Balaxi Pharmaceuticals Intrinsic Value
BALAXI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹6.05 | ₹4.84 - ₹7.26 | -70.0% | EPS: ₹0.16, Sector P/E: 22x |
| Book Value Method | asset | ₹50.45 | ₹45.41 - ₹55.50 | +150.0% | Book Value/Share: ₹210.91, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹40.36 | ₹36.32 - ₹44.40 | +100.0% | Revenue/Share: ₹210.91, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹40.36 | ₹36.32 - ₹44.40 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹42.20 | ₹33.76 - ₹50.64 | +109.1% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹6.05 | ₹5.45 - ₹6.66 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹6.05 | ₹5.45 - ₹6.66 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹27.55 | ₹24.80 - ₹30.31 | +36.5% | EPS: ₹0.16, BVPS: ₹210.91 |
Want to compare with current market value? Check BALAXI share price latest .
Valuation Comparison Chart
BALAXI Intrinsic Value Analysis
What is the intrinsic value of BALAXI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Balaxi Pharmaceuticals (BALAXI) is ₹40.36 (median value). With the current market price of ₹20.18, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹6.05 to ₹50.45, indicating ₹6.05 - ₹50.45.
Is BALAXI undervalued or overvalued?
Based on our multi-method analysis, Balaxi Pharmaceuticals (BALAXI) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.12 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.75x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Balaxi Pharmaceuticals
Additional stock information and data for BALAXI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-35 Cr | ₹-46 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹5 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹6 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹34 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |